Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antipsychotic drug has few side effects in Alzheimer’s patients

19.09.2002


A drug used to help control psychotic behavior in people with schizophrenia holds promise for controlling similar symptoms in the early stages of Alzheimer’s disease, a new study suggests.

What sets this drug – called quetiapine – apart from its contemporary counterparts is its apparent lack of serious side effects, such as confusion, muscle stiffness and imbalance in the joints, said Douglas Scharre, a study co-author and an associate professor of clinical neurology at Ohio State University.

None of the 10 subjects in the study reported any of these symptoms during a 12-week trial.



“Quetiapine should be considered the first line of treatment for psychosis in Alzheimer’s patients because of its lack of serious side effects,” Scharre said, adding that while no antipsychotic medication is currently approved by the Food and Drug Administration to treat Alzheimer’s-related psychosis, physicians can prescribe it as an “off-label” use. An estimated 4 million people in the United States have the disease.

The research appears in a recent issue of the journal Alzheimer Disease and Associated Disorders.

Scharre and co-author Shu-Ing Chang, a clinical instructor of neurology at Ohio State, prescribed quetiapine (brand name Seroquel) to patients with mild to moderate forms of Alzheimer’s disease. Their study is the first to look at the effects quetiapine may have on cognitive function in the disease.

The researchers recruited 10 outpatients with a diagnosis of probable Alzheimer’s disease and who had symptoms of psychotic or aggressive behaviors severe enough to justify drug treatment on a regular basis. Quetiapine was the only antipsychotic medication prescribed during the 12-week study.

The researchers evaluated the subjects at the beginning of the study and again at six and 12 weeks. They measured behavioral symptoms using the Neuropsychiatric Inventory and evaluated cognitive abilities using the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog). The patients also underwent a physical examination at each visit. Subjects were monitored weekly via telephone conversations.

The subjects began the study by taking 25 milligrams of quetiapine each night at bedtime. Dosages were increased by 25 mg weekly if symptoms of aggression and psychosis were still evident.

The average dose of quetiapine at the end of the study was 50 mg twice daily. Dosing ranged from 50 mg to 150 mg per patient per day, a fraction of what is normally required to control psychotic behavior in schizophrenic patients.

“Schizophrenics don’t show much of a response until the dose is 150 mg or higher, and may require up to 600 to 800 mg of quetiapine to ease psychotic symptoms,” Scharre said.

At the end of the current study, quetiapine at the 50 to 150 mg level did not significantly worsen cognitive function in the Alzheimer’s subjects. In fact, the average ADAS-cog scores improved slightly after six weeks.

“The decrease in aggression and psychotic behavior at this point may also have contributed to the improvement in cognitive scores,” Scharre said.

However, at week 12 the cognitive scores decreased slightly from what they were at the outset of the study. This most likely represents the natural result of the disease progression, and not the use of quetiapine, Scharre said.

The average Alzheimer’s patient in the early to middle stages of the disease will usually show a decrease in cognition of five to 11 points annually on the ADAS-cog scale, or about one to three points every three months. The cognition of the subjects in the current study decreased an average of 2.4 points during the 12-week study.

As for physical side effects induced by quetiapine, four out of the 10 patients in the current study reported feeling drowsy at times, but the side effect was temporary. Four of the 10 patients also gained an average of four pounds while taking the drug, which might be a welcome side effect as weight loss is a common problem in Alzheimer’s patients.

The subjects didn’t report feeling dizzy nor did they complain of stiff joints or muscles. That’s important, Scharre said, as people with the disease are elderly and prone to falling.

“While many of the currently available medications work well in controlling psychosis, they can cause confusion or Parkinson’s disease-like symptoms, such as increased stiffness and tremor.”

While he uses quetiapine to help control psychotic behavior in patients at all stages of the disease, Scharre said it’s particularly important for patients in the early stages of Alzheimer’s to take medications – such as quetiapine – that don’t increase cognitive loss.

“A physician hopes to help patients retain as much cognitive function as possible, in a disease where cognitive decline is the norm,” he said.


Contact: Douglas Scharre, 614-293-8531; Scharre.1@osu.edu
Written by Holly Wagner, 614-292-8310; Wagner.235@osu.edu

Douglas Scharre | EurekAlert!

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>